Protalix/Pfizer first in US with plant cell-based recombinant therapeutic protein
This article was originally published in Scrip
Executive Summary
For Protalix BioTherapeutics and Pfizer, the US FDA's 1 May marketing clearance of Elelyso (taliglucerase alfa), an enzyme replacement therapy (ERT) for Gaucher disease, puts the firms in the record books for gaining the first US approval of a recombinant therapeutic protein made in a plant organism – carrot cells, to be exact.
You may also be interested in...
Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip
Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.